CLS and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada
Lund, Sweden, 12 July, 2021 - Clinical Laserthermia Systems AB (publ) (CLS) , developer of high precision, image-guided focal laser ablation systems, today announced it has received approval from Health Canada for its updated sterilization documentation as well as an acceptance for its new sterilization supplier, ROSE GmbH. This means that CLS and University Health Network , that includes Toronto General Hospital in Toronto, Canada, can now resume the clinical Phase II trial, led by Dr. Sangeet Ghai, regarding MRI-